Latest Conference Articles

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Ongoing maintenance therapy is essential to avoid relapse and preserve gains in repigmentation for patients with vitiligo, according to Gina Mangin, MPAS, PA-C.

Orit Markowitz, MD, shares how a color-focused strategy helps spot early malignancies—even 2-mm lesions—across all skin tones.

A yearlong study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

Catch up on coverage from the second day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

Subcutaneous spesolimab maintained durable GPP control for 12 months after rapid clearance from IV spesolimab in a high-risk elderly patient.

Adam Friedman, MD, FAAD, outlines a stepwise approach to treating chronic hand eczema, from vehicle selection to systemic therapies and future innovations.

A poster at SDPA highlights that dermatologists play a vital role in early detection of metastatic breast cancer, with skin changes often serving as the initial clue of internal disease recurrence.

Adam Friedman, MD, FAAD, breaks down how to differentiate chronic hand eczema from similar conditions using history, morphology, and key clinical clues.

Apremilast improved joint symptoms and quality of life in patients with early oligoarticular PsA, with consistent efficacy across all BMI categories.

Janelle Ball of BC Educators offers actionable tips to boost prior authorization success and improve patient support in dermatology practices.

Catch up on coverage from the first day of the 2025 SDPA Annual Summer Dermatology Conference held in Washington, DC.

A poster at SDPA 2025 highlights the importance of early biopsy and genetic testing in aggressive cSCC, even in young patients without classic risk factors.

Almirall showcased groundbreaking research on atopic dermatitis, psoriasis, and actinic keratosis at the 2025 ICD.

DFD-29 showed strong efficacy in rosacea regardless of body weight in 2 phase 3 trials, outperforming both placebo and doxycycline.

Eileen Cheever, MPAS, PA-C, previews the SDPA Summer Dermatology Conference, calling it a can't-miss opportunity to learn, network, and reconnect.

Click here to answer our poll and let us know what you're looking forward to at the SDPA's summer conference.

Join Dermatology Times at SDPA 2025 as our expert board members take the stage to share clinical insights, pearls, and practice-changing perspectives.

The conference aimed at providing dermatology physician assistants with the latest in the specialty begins today in Washington, DC.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the final day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Anabela Cardoso, MD, shares data from the phase 3b ADmirable trial—the first study to evaluate the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.

Discover insights from Peter Lio, MD, on precision medicine in pediatric atopic dermatitis and the promising role of ruxolitinib at the RAD 2025 Conference.

At RAD 2025, Maureen Offiah, MD, reflected on the sessions she felt were the most impactful as an attendee.